Non-Alcoholic Fatty Liver Disease Clinical Trial
— NAFLDOfficial title:
The Effect of Berberine on Lipid Profile, Liver Enzymes and Fasting Blood Glucose in Patients With Non-Alcoholic Fatty Liver Disease (NAFLD): A Randomized Controlled Trial
Verified date | August 2019 |
Source | Islamic Azad University, Tehran |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Non-alcoholic fatty liver disease (NAFLD), one of the most common liver dysfunctions, affects about one-fourth of the global adult population and has a significant mortality rate between 6.3% and 33%.NAFLD can lead to other serious illnesses. The disease is associated with a group of metabolic comorbid conditions, including type 2 diabetes mellitus (T2DM), obesity, hypertension, and hyper-cholesterolemia, which are potential risk factors for progressive liver disease.This study sought to evaluate the therapeutic effect of berberine on the liver function and metabolic profiles of patients with NAFLD. In this context,A six week, open-label randomized controlled trial was conducted in a single medical center at Takestan Hospital, Iran. A total of 281 patients with NAFLD were enrolled and randomly assigned to treatment arm with (n=24) or without (n=24) berberine. All patients had received pre-randomization lifestyle training including recommendations on low-fat diet. Blood examinations were performed to evaluate glucose, lipid profile, and liver enzymes both at the beginning of the study and upon the completion of the trial (day 45). To assess tolerability of the study intervention and any possible adverse events, patients in both groups were required to attend weekly follow-up visits.
Status | Completed |
Enrollment | 50 |
Est. completion date | June 15, 2019 |
Est. primary completion date | March 25, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Patients must have an age range between 18 to 65 years(inclusive). - Patients with Liver fat content assessed by MRS=13%. - Patients must meet the criteria for impaired glucose regulation - Course of diabetic mellitus less than 1 year - Informed consent signed Exclusion Criteria: - Any causes of chronic liver disease other than NAFLD(such as-but not restricted to- alcohol or drug abuse, medication, chronic hepatitis B or C, autoimmune, etc.); - Patients with significantly impaired liver function: ALT or AST=2 times upper limit of normal; - Patients with type 1 diabetes mellitus or gestational diabetes or special type diabetes; - Course of diabetes more than 1 years; - Diabetics patients who have taken or are taking oral glucose-lowering drugs or insulin; - Diabetics patients with a HbA1c>7.5% on initial visit; - Patients with severe diabetes complications(diabetes ketoacidosis, diabetes coma or with symptomatic of diabetes coma; dysfunction of nerve, retinopathy, dysfunction of kidney); - Patients with a history of clinically significant heart disease(myocardial infarct, heart failure, and/or severe cardiac rhythm); - Complicating severe infection,within 6 months after operation, severe trauma; - Patients with excess alcohol consumption=140g/week(male); =70g/week(female); - Patients have participated other clinical trials within 24 weeks; - Patients with a history of drug allergy to berberine; - Patients with gestation or possible gestation or lactation, or males or females expecting gestation during clinical trial; - Mental diseases patients; - Those who refuse to sign informed consent; - Any other conditions, which, in the opinion of the investigators would impede competence or compliance or possibility of hindering completion of the study; - Patients with serum triglyceride=5.0mmol/L; - Patients with thyroid disease, including hyperthyroidism or hypothyroidism. |
Country | Name | City | State |
---|---|---|---|
Iran, Islamic Republic of | Sciences & Research Branch,Azad University of Tehran | Tehran |
Lead Sponsor | Collaborator |
---|---|
Lida Nejati |
Iran, Islamic Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from baseline of Alanine Aminotransferase (ALT) | Serum Alanine Aminotransferase concentration (units per liter) | Baseline and 6 weeks after | |
Primary | Change from baseline of Aspartate Aminotransferase (AST) | Serum Aspartate Aminotransferase concentration(units per liter) | Baseline and 6 weeks after | |
Primary | Change from baseline of Alkaline Phosphatase( ALP) | Serum Alkaline Phosphatase concentration (units per liter) | Baseline and 6 weeks after | |
Secondary | Change from baseline of fasting blood sugar(FBS) | Fasting blood sugar concentration (mg/dl) | Baseline and 6 weeks after | |
Secondary | Change from baseline of total cholesterol (TC) | Serum total cholesterol concentration (mg/dl) | Baseline and 6 weeks after | |
Secondary | Change from baseline of LDL-Cholesterol | Serum LDL-Cholesterol concentration (mg/dl) | Baseline and 6 weeks after | |
Secondary | Change from baseline of HDL - Cholesterol | Serum HDL-Cholesterol concentration (mg/dl) | Baseline and 6 weeks after | |
Secondary | Change from baseline of Triglyceride (TG) | Serum Triglyceride concentration (mg/dl) | Baseline and 6 weeks after |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05480696 -
Soluble Fibre Supplementation in NAFLD
|
Phase 1 | |
Active, not recruiting |
NCT02500147 -
Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS)
|
Phase 4 | |
Completed |
NCT04671186 -
Role of Probiotics in Treatment of Pediatric NAFLD Patients by Assessing With Fibroscan
|
N/A | |
Recruiting |
NCT05979779 -
Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis
|
Phase 2 | |
Recruiting |
NCT05462353 -
Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 Tablets in Adult Patients With NASH
|
Phase 2 | |
Completed |
NCT05006885 -
ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)
|
Phase 1 | |
Completed |
NCT04117802 -
Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome
|
N/A | |
Recruiting |
NCT04365855 -
The Olmsted NAFLD Epidemiology Study (TONES)
|
N/A | |
Recruiting |
NCT05618626 -
Prevention of NAFLD and CVD Through Lifestyle Intervention
|
N/A | |
Completed |
NCT03256526 -
6-week Safety and PD Study in Adults With NAFLD
|
Phase 2 | |
Enrolling by invitation |
NCT06152991 -
Clinical Trial Assessing Godex Carnitine Orotate Complex in Nonalcoholic Fatty Liver Disease Patients for Efficacy
|
Phase 3 | |
Completed |
NCT03681457 -
Evaluation of the Pharmacokinetics of Tropifexor in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Healthy Control Subjects
|
Phase 1 | |
Completed |
NCT06244550 -
Clinical Trials Using HepatoKeeper Herbal Essentials to Treat Non-alcoholic Fatty Liver Disease and Metabolic Factors
|
N/A | |
Not yet recruiting |
NCT05120557 -
Point-of-care Ultrasound Screening and Assessment of Chronic Liver Diseases and NASH
|
N/A | |
Completed |
NCT03060694 -
Screening Diabetes Patients for NAFLD With Controlled Attenuation Parameter and Liver Stiffness Measurements
|
||
Completed |
NCT02526732 -
Hepatic Inflammation and Physical Performance in Patients With NASH
|
N/A | |
Recruiting |
NCT01988441 -
The Influence of Autophagy on Fatty Liver
|
||
Recruiting |
NCT01680003 -
Hepar-P Study to Evaluate the Safety and Efficacy of a Standardised Extract of Phyllanthus Niruri for the Treatment of Non-alcoholic Fatty Liver Disease
|
Phase 2 | |
Completed |
NCT01712711 -
Helicobacter Pylori Eradication in Diabetic Subjects With Non-alcoholic Fatty Liver Disease
|
Phase 2 | |
Recruiting |
NCT00941642 -
Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease
|
Phase 4 |